METABOLIC DISORDERS

Pharmidex can provide in vitro assays and in vivo animal models to investigate the efficacy of the compounds in metabolic disorders (obesity, diabetes, NASH) and kidney diseases including AKPKD (autosomal dominant polycystic kidney disease).

Obesity

  • Diet induced Obesity (DIO)
  • Diet induced NASH (Non-alcoholic Steatohepatitis)
  • Duration : Maximum 40 weeks
  • Species: Rat, Mice
  • Routes of Administration: IV, PO, SC, IP, IN
  • Genetic models : Rat and Mice
  • Zucker fatty rats
  • Body weight glucose tolerance, insulin sensitivity and/or insulin tolerance
  • Biomarkers analysis

Diabetes

  • Chemically Induced Model (Streptozotocin, Alloxan)
  • Duration : Maximum 40 weeks
  • Species: Rat, Mice
  • Routes of Administration: IV, PO, SC, IP, IN
  • Genetic models : Rat and Mice Zucker Diabetic Fatty (ZDF) Rat, AKITA MICE, db/db.
  • Body weight glucose tolerance, insulin sensitivity and/or insulin tolerance
  • Biomarkers analysis

Kidney Diseases

  • Chemically Induced Model (Adriamycin, Folic acid)
  • Allergen Induced Model (LPS)
  • Tamoxifen Induced ADPKD
  • Duration : Maximum 30 weeks
  • Species: Rat, Mice
  • Routes of Administration: IV, PO, SC, IP, IN
  • Genetic models : Rat and Mice
  • Urine analysis and imaging
Share by: